Rep. Foxx Is Selling Shares of This Covid Vaccine Maker
Congresswoman Virginia Foxx, Republican Leader of the House Committee on Education and Labor, disclosed on the 8th of August that she sold between $100,000 and $250,000 worth of shares of GlaxoSmithKline PLC, the UK-based pharma giant.
This is the biggest trade disclosed by Foxx in this filing, in addition to taking a long position in The Toronto-Dominion Bank. Foxx disclosed she sold shares on July 12 at $41.44.GSK shares closed at $40.31 on the 8th of August.
Six days before selling shares, Foxx also took a small stake in GSX worth between $1,000 and $15,000 at an average price of $43.11, a filing showed.
Congresswoman’s trades in GSK came a few weeks after the pharma titan reported that its vaccine candidate, developed together with Sanofi, delivered 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19.
Against the Omicron variant, the Covid vaccine candidate showed 72% efficacy in all adults and 93.2% in seropositives.
Roger Connor, President of GSK Vaccines, commented: “These positive data show efficacy of our protein-based, bivalent adjuvanted vaccine candidate in an environment of high Omicron variant circulation. Our vaccine candidate has the potential to make an important contribution to public health as the pandemic evolves further.”
In addition to GSK trades, Foxx also disclosed other investing activating in a series of filings published. The U.S. representative for North Carolina's 5th congressional district also traded shares of Universal Corp., Procter & Gamble, Magellan Midstream Partners, Kellogg, Alliance Resource Partners, etc.
Foxx made a total of 55 trades in the last 3 months.
